肥胖与原发性免疫性血小板减少症患者糖皮质激素治疗不良结局相关
该回顾性研究纳入齐鲁医院214例接受标准大剂量地塞米松治疗的初治原发性免疫性血小板减少症(ITP)患者,分析体重指数与疗效的关系。肥胖组总体初始反应率和初始完全反应率均显著低于体重不足、正常和超重各组,6个月持续反应和持续完全反应也呈相同趋势,肥胖组缓解持续时间缩短。多因素回归显示肥胖是初始及持续反应不良和复发风险增加的独立相关因素。
要点
- 肥胖组ITP患者初始总体反应率52.3%,低于体重不足组85.7%、正常组85.2%和超重组72.0%(p=0.001)。
- 肥胖组初始完全反应率27.3%,低于体重不足组71.4%、正常组70.4%和超重组53.3%(p<0.001)。
- 肥胖组中位缓解持续时间1个月,短于体重不足组未达到、正常组16个月和超重组2个月(p=0.002)。
核心结论
- 肥胖是糖皮质激素治疗ITP结局的负面预测因素。
- 根据体重指数状态进行分层策略可能有助于ITP的精准管理。
研究设计与样本
- 回顾性研究,纳入齐鲁医院214例接受标准大剂量地塞米松治疗的初治ITP患者。
主要发现
- 肥胖组总体初始反应率52.3%,体重不足组85.7%、正常组85.2%、超重组72.0%(p=0.001)。
- 肥胖组初始完全反应率27.3%,体重不足组71.4%、正常组70.4%、超重组53.3%(p<0.001)。
- 肥胖组6个月持续反应率22.7%,体重不足组63.6%、正常组52.3%、超重组35.6%(p=0.03)。
- 肥胖组6个月持续完全反应率9.1%,体重不足组36.4%、正常组44.6%、超重组24.4%(p=0.01)。
- Kaplan-Meier分析显示肥胖组缓解持续时间缩短,中位缓解持续时间肥胖组1个月,体重不足组未达到、正常组16个月、超重组2个月(p=0.002);多因素回归分析中肥胖与初始及持续反应不良和复发风险增加独立相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Emerging evidence has demonstrated that obesity impacts multiple immune-related diseases. It remains unclear whether and how obesity alters treatment outcomes in patients with primary immune thrombocytopenia (ITP). Thus, we retrospectively investigated 214 treatment-naïve patients who received standard high-dose dexamethasone therapy in Qilu Hospital. Patients with obesity showed significantly lower overall initial response (underweight vs. normal vs. overweight vs. obese: 85.7% vs. 85.2% vs. 72.0% vs. 52.3%, p = 0.001) and initial complete response ([CR], 71.4% vs. 70.4% vs. 53.3% vs. 27.3%, p < 0.001) rates. The same trend was observed in the 6-month sustained response (63.6% vs. 52.3% vs. 35.6% vs. 22.7%, p = 0.03) and sustained CR (36.4% vs. 44.6% vs. 24.4% vs. 9.1%, p = 0.01). The Kaplan-Meier analysis revealed a shortened duration of remission in the obese group (median duration of remission, not reached vs. 16 months vs. 2 months vs. 1 month, p = 0.002). In multivariate regression analysis, obesity was independently associated with poor initial and sustained responses, and an increased risk for relapse. In conclusion, obesity is a negative predictor for outcomes of corticosteroid treatment. A stratified strategy according to body mass index status may facilitate the precision management of ITP.
引用
- Zhang X, Liu Q, Liu A, et al. Obesity is associated with poor outcomes of corticosteroid treatment in patients with primary immune thrombocytopenia. Br J Haematol. 2023. PMID: 37488467. doi:10.1111/bjh.18997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。